Statements (104)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:cancer_treatment
|
| gptkbp:administered_by |
intravenous infusion
oncologists |
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:can_cause |
cytokine release syndrome
|
| gptkbp:can_lead_to |
long-term remission
|
| gptkbp:developed_by |
gptkb:University_of_Pennsylvania
patient's own T cells hematological cancers |
| gptkbp:field |
gptkb:gene_therapy
|
| gptkbp:has_a_focus_on |
pharmaceutical companies
|
| gptkbp:has_a_high_cost_of |
treatment
|
| gptkbp:has_been_shown_to_be_effective_in |
children and adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
CAR T-cell therapy
|
| gptkbp:includes |
gptkb:Yescarta
gptkb:Kymriah |
| gptkbp:involves |
chimeric antigen receptors
genetically modifying T cells leukapheresis lymphodepletion chemotherapy |
| gptkbp:involves_the_infusion_of |
modified T cells
|
| gptkbp:is_a_form_of |
gptkb:Cell
experimental therapy adaptive cell transfer |
| gptkbp:is_a_promising_approach_for |
gptkb:cancer_treatment
|
| gptkbp:is_a_subject_of |
gptkb:guidelines
ongoing research |
| gptkbp:is_associated_with |
high cost
neurotoxicity high response rates long-term remission complex manufacturing process tumor lysis syndrome serious side effects |
| gptkbp:is_based_on |
chimeric antigen receptor technology
|
| gptkbp:is_challenged_by |
ethical considerations
limited availability regulatory hurdles long wait times access issues manufacturing delays high treatment costs patient eligibility criteria insurance coverage problems need for specialized centers training requirements for staff |
| gptkbp:is_characterized_by |
high response rates
|
| gptkbp:is_compared_to |
traditional chemotherapy
|
| gptkbp:is_considered |
personalized medicine
|
| gptkbp:is_considered_as |
a breakthrough therapy
breakthrough therapy |
| gptkbp:is_discussed_in |
medical conferences
|
| gptkbp:is_documented_in |
gptkb:literature
|
| gptkbp:is_evaluated_by |
safety and efficacy
|
| gptkbp:is_explored_in |
research studies
|
| gptkbp:is_monitored_by |
adverse effects
|
| gptkbp:is_often_used_in |
other treatments
|
| gptkbp:is_part_of |
gptkb:immunotherapy
precision medicine cellular therapies |
| gptkbp:is_personalized |
treatment
|
| gptkbp:is_promoted_by |
patient advocacy groups
|
| gptkbp:is_recognized_by |
NCI
|
| gptkbp:is_regulated_by |
health authorities
|
| gptkbp:is_studied_for |
gptkb:Oncology
autoimmune diseases |
| gptkbp:is_supported_by |
government grants
pharmaceutical companies |
| gptkbp:is_used_for |
hematologic cancers
|
| gptkbp:is_used_in |
clinical trials
|
| gptkbp:is_visible_from |
improve survival rates
|
| gptkbp:requires |
leukapheresis
patient's own T cells |
| gptkbp:research |
solid tumors
|
| gptkbp:side_effect |
cytokine release syndrome
neurological toxicities |
| gptkbp:suitable_for |
all patients
patients with active infections patients with severe comorbidities patients with certain autoimmune diseases |
| gptkbp:targets |
gptkb:CD19
|
| gptkbp:technique |
engineering immune cells
|
| gptkbp:treatment |
gptkb:Oncology
requires specialized facilities diffuse large B-cell lymphoma can be life-saving requires informed consent can be personalized for each patient can induce remission has shown promise in trials. relapsed or refractory cancer |
| gptkbp:type_of |
gptkb:immunotherapy
targeted therapy cellular immunotherapy biologic therapy |
| gptkbp:used_for |
B-cell malignancies
|
| gptkbp:uses |
genetically modified T cells
|
| gptkbp:was_first_approved_in |
gptkb:2017
|
| gptkbp:bfsParent |
gptkb:Oncology
gptkb:Cancer_Immunotherapy gptkb:non-Hodgkin_lymphoma gptkb:Celgene |
| gptkbp:bfsLayer |
4
|